Beta Drugs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹137 Cr +33% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
BD

Beta Drugs Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Beta Drugs Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹126Cr
+26% YoY
+34% QoQ
Net profit
₹16Cr
+33.3% YoY
+77.8% QoQ
Margin
22%
+2 pp YoY
+3 pp QoQ

Beta Drugs Ltd Q1 FY27 key numbers

Revenue
Branded Oncology business grew 47% YoY, sales INR 330 Mn.

As stated in Beta Drugs Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Beta Drugs Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,093
Market cap₹2.3K Cr
P/E50.0

The short version

Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F

From Beta Drugs Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32).
  • EBITDA for Q1-FY27: INR 274 Mn, +39.1% YoY (Page 32).
  • PAT for Q1-FY27: INR 165 Mn, +41.0% YoY (Page 32).
  • Branded Oncology business grew 47% YoY, sales INR 330 Mn (Page 31).
  • Contract Manufacturing (CMO) grew 41% YoY (Page 31).
  • Exports revenue in Q1-FY27: INR 172 Mn (Page 30).
  • Domestic Branded Formulations revenue contribution was 36% for FY26; Nivian IVF revenues consolidated from FY27 (Page 5).

2 more points from Beta Drugs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation mentions the following capex, capacity expansion, and new projects: - **EU GMP-aligned Infrastructure Expansion**: Part of export expansion strategy to support dossier filings, product registration, and deeper market penetration (Page 23). - **Three WHO-GMP Certified Manufacturing Facilities**: Existing facilities with strong manufacturing capabilities, including one with additional accreditations (Page 22). - **API Manufacturing Infrastructure Expansion**: Modern API manufacturing capabilities supporting backward integration and cost-efficiency, with a focus on expanding API capabilities for global markets and future products (Page 20).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides insights related to business momentum and demand: - Export business generated INR 172 Mn revenue in Q1-FY27, with management expecting stronger momentum and accelerated order inflows over the remainder of FY27 (Page 31). - The Contract Manufacturing (CMO) business showed robust growth (41% YoY) supported by strong traction with customers and new launches (Page 31).

Beta Drugs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Beta Drugs Ltd Q1 FY27 results — key figures

Beta Drugs Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue126100+26%94+34%
Operating profit (EBITDA)2720+35%18+50%
Operating margin22%20%+2 pp19%+3 pp
Profit before tax2216+37.5%12+83.3%
Net profit (PAT)1612+33.3%9+77.8%
EPS (₹)14.2511.59+23%8.93+59.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹137 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Beta Drugs Ltd Q1 FY27 results?

Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F

What is Beta Drugs Ltd share price analysis?

Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 50.0 with a market cap of ₹2,278 Cr. Investors should review the full earnings analysis for detailed insights.

Is Beta Drugs Ltd planning capital expenditure?

The presentation mentions the following capex, capacity expansion, and new projects: - EU GMP-aligned Infrastructure Expansion: Part of export expansion strategy to support dossier filings, product registration, and deeper market penetration (Page 23).

Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.